GRI Bio Reports Q1 2026 Financial Results with Reduced Net Loss and Increased Cash Reserves

GRI Bio, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $1.998 million, a decrease from a net loss of $3.046 million in the same period of 2025. The company's total operating expenses for the quarter were $2.003 million, down from $3.051 million year-over-year, primarily due to a significant reduction in research and development expenses, which fell from $1.640 million to $361,000. This decrease was attributed to the completion of the Phase 2a clinical trial for its lead product candidate, GRI-0621, which targets severe fibrotic lung diseases.

In terms of liquidity, GRI Bio reported cash and cash equivalents of approximately $11.048 million as of March 31, 2026, an increase from $8.229 million at the end of 2025. The company raised $6.504 million through its At The Market (ATM) Offering during the quarter, selling 1,087,364 shares at a weighted average price of $6.27 per share. This funding is crucial as GRI Bio continues to navigate its clinical development programs and operational costs, with an accumulated deficit of $53.694 million as of the end of the quarter.

Strategically, GRI Bio has been focused on advancing its clinical programs, particularly GRI-0621, which is in development for idiopathic pulmonary fibrosis (IPF). The company has reported positive preliminary results from its Phase 2a trial, indicating that GRI-0621 was well-tolerated and showed potential anti-fibrotic effects. The trial met its primary endpoint of safety and tolerability, and secondary endpoints suggested improvements in biomarkers associated with fibrosis. GRI Bio plans to initiate a Phase 2b trial, contingent on securing additional funding.

Operationally, GRI Bio's employee headcount remains stable, with no significant changes reported. The company continues to evaluate its product pipeline, which includes GRI-0803, aimed at treating autoimmune disorders. GRI Bio's management has indicated that while they expect to incur significant operating losses in the near future, they believe their existing cash reserves will be sufficient to fund operations into the second quarter of 2027, assuming they continue with preliminary work on GRI-0621.

Looking ahead, GRI Bio acknowledges the need for additional capital to support its clinical trials and operational expenses. The company intends to pursue further equity financing and potential collaborations to secure the necessary resources. However, there is substantial uncertainty regarding the availability of such financing, which could impact the company's ability to continue its operations and development programs.